At the end of last month, Misonix and Sonora Medical Systems received FDA approval for a 3-D surface-rendering tool called BabyFace that, when plugged into a standard ultrasound system, transforms a 2-D image of a fetus into 3-D.The system uses a
At the end of last month, Misonix and Sonora Medical Systems received FDA approval for a 3-D surface-rendering tool called BabyFace that, when plugged into a standard ultrasound system, transforms a 2-D image of a fetus into 3-D.
The system uses a transducer with an integrated motion-tracking sensor and a compact electronic box with a miniature computer. Product developers of BabyFace say the software can connect easily to conventional ultrasound systems.
Sonora, a distributor of previously owned and refurbished medical imaging systems, developed BabyFace with Biomedicom of Israel. Biomedicom is a spin-off of Mountain View, CA-based Silicon Graphics. Misonix President Michael A. McManus said his company will market the rendering tool aggressively. Misonix has a larger than 50% interest in Sonora.
Integrated Equipment Solutions, distributor of BabyFace, showed off the software at the American Institute of Ultrasound Medicines convention in San Francisco this month. BabyFace will also be shown at the May 2224 American College of Obstetricians and Gynecologists meeting in San Francisco.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.